Robert Steven Davidson - Nov 17, 2016 Form 4 Insider Report for Cure Pharmaceutical Holding Corp. (AVRW)

Role
Chief Executive Officer, Director
Signature
/s/ Robert Davidson
Stock symbol
AVRW
Transactions as of
Nov 17, 2016
Transactions value $
$4,439
Form type
4
Date filed
5/25/2021, 06:01 AM
Next filing
May 24, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVRW Common Stock Gift $0 -25K -4.55% $0.00 525K Oct 10, 2018 Direct F1
transaction AVRW Common Stock Award $0 +31.3K +5.96% $0.00 556K Jul 1, 2019 Direct F2
transaction AVRW Common Stock Purchase $4.44K +6.44K +1.16% $0.69* 562K May 24, 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVRW Stock Option Award $0 +354K $0.00 354K Nov 7, 2016 Common Stock 354K $0.74 Direct F4
transaction AVRW Stock Option Award $0 +68.8K $0.00 68.8K May 7, 2018 Common Stock 68.8K $0.61 Direct F4
transaction AVRW Stock Option Award $0 +225K $0.00 225K Apr 11, 2019 Common Stock 225K $3.40 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person transferred 25,000 shares of common stock to his son as a bona-fide gift. This late filing is due to an inadvertent administrative error and not any error of the reporting person.
F2 Represents shares of common stock received upon vesting of a restricted stock award. This late filing is due to an inadvertent administrative error and not any error of the reporting person.
F3 This is the weighted average purchase price. Shares were purchased in multiple transactions at prices from $0.68422 to $0.69350. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. The amount reflected has been rounded to 3 decimal points.
F4 The option becomes exercisable on the basis determined by the equity incentive plan with 6.25% of the option vesting on the first quarter anniversary of vesting start date. For each additional quarter of the participant's service the option will continue to vest until the vested ratio is 100%. This late filing is due to an inadvertent administrative error and not any error of the reporting person.